Nuria Izquierdo-Useros is an expert in Infectiology at Instituto de Salud Carlos III (Spain). Nuria Izquierdo-Useros has authored 150 publications, the most recent in 2026, and is an investigator in 4 clinical trials. SLR score: 484 (community average: 125). How the SLR is computed.

LeadR Profile

Nuria Izquierdo-Useros Instituto de Salud Carlos III Spain
484 ScienceLeadR Reputation 484
Network Map

Infectiology

Subspecialties: Biochemistry - Immunology - Pharmacy

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 2006 - 2026

Source: PubMed

IrsiCaixa

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 150

Citations

Citations: 5 052 1st author: 11 Last author: 22 Unique author: 1


Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Retrotransposons as both "architects" and "saboteurs" in the nervous system.
PMID 42219645 — genetics, aging, brain, therapeutics, nervous system
Adv Genet20250
Airway organoids reveal patterns of influenza A tropism and adaptation in wildlife species.
PMID 41997892 — tropism, viral tropism, disease outbreaks, organoids, influenza, human, viruses, physical exertion, infections
Emerg Microbes Infect20260
Optimized ACE2-Fc fusion proteins with picomolar neutralization activity against highly evolved SARS-CoV-2 variants.
PMID 41603290 — coronavirus, sars-cov-2, viruses, antibodies, monoclonal, severe acute respiratory syndrome-related coronavirus
Protein Sci20260
Anti-SARS-CoV-2 antibodies from severe COVID-19 individuals or S2 immunizations do not worsen disease in hamsters.
PMID 41286076 — sars-cov-2, immunization, antibodies, covid-19, severe acute respiratory syndrome-related coronavirus
Commun Biol20250
Pharmacological reprogramming of plitidepsin as a SARS-CoV-2 inhibitor.
PMID 41218566 — sars-cov-2, pharmaceutical preparations, neoplasms, therapeutics, severe acute respiratory syndrome-related coronavirus
Mol Aspects Med20250

Clinical Studies 4

Sources: ClinicalTrials, EU CTIS

Synthesis

By phase:

N/A 1
Phase 1 1
Phase 1/Phase 2 1
Phase 2 1

By status:

Completed 4

By type:

Interventional 4

By Monocentric/Multicentric:

monocentric 1
multicentric2to4 1
multicentric5to9 0
multicentricup10 2

Main Topics

Cohort/Consortium Investigators 1

LeadR Networks

Main global connection map